Table 3 Combining multiple test as two-test parallel (A) and serial (B) combination
From: Biomarkers for screening of lung cancer and pre-neoplastic lesions in a high risk Chilean population
Test A | Sensitivity % (95% CI) | Specificity % (95% CI) | PPV % (95% CI) | PNV % (95% CI) | ||||
|---|---|---|---|---|---|---|---|---|
LC | PNL | LC | PNL | LC | PNL | LC | PNL | |
DR70 | 95.8 (78.9- 99.9) | 27.3 (6.0-61.0) | 91.9 (88.1-94.8) | 91.9 (88.1-94.3) | 50.0 (35.1 -65.1) | 11.5 (2.4 -30.2) | 99.6 (97.8 -100) | 97.0 (94.2 -98.7) |
AQC | 64.0 (42.5- 82.0) | 90.9 (58.7-99.8) | 89.4 (85.2-92.7) | 89.4 (85.2-92.7) | 34.8 (21.2 -50.4) | 25.0 (12.6 -41.4) | 96.6 (93.6 -98.6) | 99.6 (97.8 -100) |
Parallel combined test | 92.0 (74.4 -100) | 91.2 (83.0-99.5) | 80.92 (76.2-85.7) | 80.92 (76.2-85.7) | 29.9 (19.0 -40.7) | 49.1 (39.1 -59.1) | 99.1 (97.7 -100) | 97.9 (95.8 -99.9) |
Test B | Sensitivity % (95% CI) | Specificity % (95% CI) | PPV % (95% CI) | PNV % (95% CI) | ||||
LC | PNL | LC | PNL | LC | PNL | LC | PNL | |
DR70 | 95.8 (78.9- 99.9) | 27.3 (6.0-61.0) | 91.9 (88.1-94.8) | 91.9 (88.1-94.3) | 50.0 (35.1 -65.1) | 11.5 (2.4 -30.2) | 99.6 (97.8 -100) | 97.0 (94.2 -98.7) |
AQC | 64.0 (42.5- 82.0) | 90.9 (58.7-99.8) | 89.4 (85.2-92.7) | 89.4 (85.2-92.7) | 34.8 (21.2 -50.4) | 25.0 (12.6 -41.4) | 96.6 (93.6 -98.6) | 99.6 (97.8 -100) |
Serial combined test | 60.0 (38.8 -81.2) | 35.1 (21.8 -48.4) | 97.2 (95.1 -99.3) | 97.2 (95.1-99.3) | 65.2 (43.6 -86.9) | 71.4 (52.9 -90.0) | 96.5 (94.2 -98.8) | 88.1 (84.4 -91.9) |